Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [3922]

PARP inhibitor olaparib as treatment for pancreatic cancer patients with BRCA...

Dr Hedy Kindler - University of Chicago, Chicago, USA

PARP inhibitor olaparib as treatment for pancreatic cancer patients with BRCA gene mutations ( Dr Hedy Kindler - University of Chicago, Chicago, USA )

Enzalutamide as treatment for men with mHSPC who have received testosterone...

Dr Christopher Sweeney - Dana-Farber Cancer Institute, Boston, USA

Enzalutamide as treatment for men with mHSPC who have received testosterone suppression ( Dr Christopher Sweeney - Dana-Farber Cancer Institute, Boston, USA )

Enzalutamide improves survival for men with metastatic hormone-sensitive...

Dr Christopher Sweeney - Dana-Farber Cancer Institute, Boston, USA

Enzalutamide improves survival for men with metastatic hormone-sensitive prostate cancer ( Dr Christopher Sweeney - Dana-Farber Cancer Institute, Boston, USA )

Comment: Using enzalutamide will allow patients to avoid chemotherapy and...

Dr Neeraj Agarwal - Huntsman Cancer Institute, Salt Lake City, USA

Comment: Using enzalutamide will allow patients to avoid chemotherapy and steroids improving quality of life ( Dr Neeraj Agarwal - Huntsman Cancer Institute, Salt Lake City, USA )

Maintenance therapy with PARP inhibitor olaparib delays progression in patients...

Dr Hedy Kindler - University of Chicago, Chicago, USA

Maintenance therapy with PARP inhibitor olaparib delays progression in patients with BRCA-related pancreatic cancer ( Dr Hedy Kindler - University of Chicago, Chicago, USA )

Comment: It is essential to identify the BRCA gene in pancreatic cancer...

Dr Suzanne Cole - UT Southwestern Medical Center, Dallas, USA

Comment: It is essential to identify the BRCA gene in pancreatic cancer patients allowing them to be treated with an oral agent ( Dr Suzanne Cole - UT Southwestern Medical Center, Dallas, USA )

Improving cancer care outcomes in Ghana through mentorship

Dr Verna Vanderpuye - Korle Bu Teaching Hospital, Accra, Ghana

Improving cancer care outcomes in Ghana through mentorship ( Dr Verna Vanderpuye - Korle Bu Teaching Hospital, Accra, Ghana )

Clinical and translational results from the NEOSTAR study: Treating early-stage...

Dr Tina Cascone - The University of Texas MD Anderson Cancer Center, Houston...

Clinical and translational results from the NEOSTAR study: Treating early-stage lung cancer with nivolumab plus ipilimumab ( Dr Tina Cascone - The University of Texas MD Anderson Cancer Center, Houston, USA )

AXL inhibitor bemcentinib in combination with chemotherapy exerts anti...

Dr Sonja Loges - University Hospital Eppendorf, Hamburg, Germany

AXL inhibitor bemcentinib in combination with chemotherapy exerts anti-leukaemic activity in AML patients ( Dr Sonja Loges - University Hospital Eppendorf, Hamburg, Germany )

Biomarker analysis from JAVELIN Renal 101: Avelumab plus axitinib versus...

Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA

Biomarker analysis from JAVELIN Renal 101: Avelumab plus axitinib versus sunitinib in aRCC ( Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA )

PARP inhibitors are a promising alternative to chemotherapy for patients with...

Dr Sara A. Hurvitz - UCLA Jonsson Comprehensive Cancer Center, Los Angeles, USA

PARP inhibitors are a promising alternative to chemotherapy for patients with metastatic BRCA1 and BRCA2 breast cancer ( Dr Sara A. Hurvitz - UCLA Jonsson Comprehensive Cancer Center, Los Angeles, USA )

MONALEESA-7: Results from phase III trial looking at ribociclib as an addition...

Dr Sara A. Hurvitz - UCLA Jonsson Comprehensive Cancer Center, Los Angeles, USA

MONALEESA-7: Results from phase III trial looking at ribociclib as an addition to endocrine therapy in advanced breast cancer ( Dr Sara A. Hurvitz - UCLA Jonsson Comprehensive Cancer Center, Los Angeles, USA )

More from ecancer